Literature DB >> 12428265

Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.

Marcela Cisternas, Miguel Gutiérrez, Sergio Jacobelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12428265     DOI： 10.1002/art.10488

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  10 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 3.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

Review 4.  Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy.

Authors:  T Umapathi; Richard A C Hughes; Eduardo Nobile-Orazio; Jean-Marc Léger
Journal:  Cochrane Database Syst Rev       Date:  2015-03-04

5.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 6.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 7.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

8.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16

9.  Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.

Authors:  Evripidis Kaltsonoudis; Anastasia K Zikou; Paraskevi V Voulgari; Spyridon Konitsiotis; Maria I Argyropoulou; Alexandros A Drosos
Journal:  Arthritis Res Ther       Date:  2014-06-17       Impact factor: 5.156

10.  Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.

Authors:  Claudia Bruè; Cesare Mariotti; Ilaria Rossiello; Andrea Saitta; Alfonso Giovannini
Journal:  Case Rep Ophthalmol       Date:  2016-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.